The Role of Erythropoietin in the Anemia of Myelodysplastic Syndrome
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma
- Vol. 4, S36-S40
- https://doi.org/10.3816/clm.2003.s.007
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Bone marrow transplantation for myelodysplasiaBlood Reviews, 2000
- Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly PatientsJournal of Clinical Oncology, 2000
- Treatment of myelodysplastic syndromes with recombinant human erythropoietinEuropean Journal of Haematology, 1991
- Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes [see comments]Blood, 1991
- Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasiaBritish Journal of Haematology, 1991
- The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietinBritish Journal of Haematology, 1991
- Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemiaCancer, 1990
- Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemiaThe International Journal of Cell Cloning, 1990
- The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromesCancer, 1989
- Circulating erythropoietin in patients with myelodysplastic syndromesBritish Journal of Haematology, 1989